Decitabine/Cedazuridine Earns European Approval in Acute Myeloid Leukemia

News
Article

Data from the phase 3 ASCERTAIN trial support the European Commission’s approval of oral decitabine and cedazuridine as a treatment for those with newly diagnosed acute myeloid leukemia.

The FDA approved oral decitabine and cedazuridine in adult patients with MDS in July 2020.

The FDA approved oral decitabine and cedazuridine in adult patients with MDS in July 2020.

The European Commission has approved oral decitabine and cedazuridine (Inqovi) for treating adult patients with newly diagnosed acute myeloid leukemia (AML) who are unable to receive standard induction chemotherapy, according to a press release from Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc.1

Supporting data for the European approval came from the phase 3 ASCERTAIN trial (NCT03306264). In the trial, oral decitabine and cedazuridine demonstrated pharmacokinetic exposure equivalence to intravenous decitabine administered across a standard 5-day schedule, thereby meeting the study’s primary end point. Additionally, the safety profile of the fixed-dose oral combination was comparable with that of intravenous decitabine.

In the open-label phase 3 ASCERTAIN trial, patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia, and AML were randomly assigned to one of 2 treatment arms. In the experimental arm, patients received 100 mg of cedazuridine plus 35 mg of decitabine orally as part of 28-day cycles. In the comparator arm, patients received 20 mg/m2 of intravenous decitabine daily.

The European Medicines Agency accepted the marketing authorization application for oral decitabine and cedazuridine in AML not eligible to be treated with induction chemotherapy in August 2022.2

The FDA approved oral decitabine and cedazuridine in adult patients with MDS in July 2020.3 Supporting data for this approval came from the phase 1/2 ASTX727-01-B trial (NCT02103478) and the ASCERTAIN trial.

References

  1. Otsuka and Astex announce that the European Commission has approved INAQOVI® (oral decitabine and cedazuridine) for the treatment of adults with newly diagnosed acute myeloid leukaemia. News release. Otsuka Pharmaceutical Europe Ltd. and Astex Pharmaceuticals, Inc. September 19, 2023. Accessed September 20, 2023. https://shorturl.at/pzGV6
  2. European Medicines Agency commences review of oral fixed-dose combination of decitabine and cedazuridine for the treatment of adults with acute myeloid leukemia. News release. Astex Pharmaceuticals. August 22, 2022. Accessed September 20, 2023. https://shorturl.at/muzR6
  3. FDA approves oral combination of decitabine and cedazuridine for myelodysplastic syndromes. News release. FDA. July 7, 2020. Accessed September 20, 2023. https://bit.ly/3pHeQhk
Related Videos
Mikkael A. Sekeres, MD, discusses how data from the phase 3 QuANTUM-First trial may advance the treatment field for patients with newly diagnosed FLT3-ITD–positive acute myeloid leukemia.
An expert from Duke Health says that patients with NPM1-mutatant relapsed/refractory acute myeloid leukemia did not experience any significant safety signals following treatment with ziftomenib.
At the recommended 600 mg dose, ziftomenib interestingly produced complete remissions in patients relapsed/refractory acute myeloid leukemia who harbored NPM1 mutations .
An expert from Duke Health reviews the design of the phase 1/2 trial of the KOMET-001 study in heavily pretreated patients with relapsed/refractory acute myeloid leukemia.
Related Content
EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

EU's CHMP Recommends Subcutaneous Atezolizumab Approval in Multiple Cancers

November 28th 2023
Article

Data from the phase 1b/3 IMscin001 trial support the Committee for Medicinal Products for Human Use’s positive opinion on subcutaneous atezolizumab in lung cancer and other disease types.

Immunotherapy Approaches in AML

Immunotherapy Approaches in AML

January 17th 2019
Podcast

Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.

CHMP Shares Positive Opinion of Momelotinib for Myelofibrosis/Anemia

November 13th 2023
Article

If momelotinib receives approval in the European Union, it will become the only agent for the treatment of myelofibrosis coupled with moderate to severe anemia.

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.

ATRA/Chemo Does Not Improve OS/Toxicity in NPM1+ Acute Myeloid Leukemia

November 3rd 2023
Article

Adding all-trans retinoic acid to chemotherapy does not appear to improve complete remission rates compared with chemotherapy alone in patients with NPM1-mutated acute myeloid leukemia.

Currently, dostarlimab has conditional approval as a monotherapy for treating adult patients with dMMR/MSI-H, recurrent or advanced endometrial cancer that has progressed. If the European Commission approves dostarlimab plus chemotherapy, it is expected that the conditional approval will convert to a full approval.

Dostarlimab/Chemo Earns Positive CHMP Opinion in Advanced Endometrial Cancer

October 26th 2023
Article

Data from the phase 3 RUBY/ENGOT-EN6/GOG3031/NSGO trial support the use of frontline dostarlimab plus chemotherapy for dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.

Adjuvant Pembrolizumab Earns European Approval for High-Risk NSCLC

October 26th 2023
Article

Data from the phase 3 KEYNOTE-091 trial supported the European Commission’s approval of pembrolizumab as an adjuvant treatment for adults with non–small cell lung cancer at high risk of recurrence following complete resection and platinum-based chemotherapy.